EyePoint phase 3 for AMD disappoints, tanking stock
Latest Fierce Pharma coverage of EyePoint phase 3 for AMD disappoints, tanking stock
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious eye disorders, including age-related macular degeneration (AMD) and diabetic macular edema. Its lead program, DURAVYU, is an intravitreal implant delivering a tyrosine kinase inhibitor for sustained VEGF suppression.
Company Info
Sector:Ophthalmology / Biopharmaceuticals
Headquarters:Watertown, Massachusetts, USA
Founded:2005
Website:eyepoint.bio/
Recent News
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
Reuters reports EyePoint's eye drug missed its main goal in a late-stage trial, sending shares tumbling.
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
BioSpace reports EyePoint Pharmaceuticals stock dropped sharply after its Phase 3 AMD drug failed, intensifying the next-generation macular degeneration competition.